Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!

Literature DB >> 22576730

Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!

Dominique Hillaire-Buys, Jean-Luc Faillie, Jean-Louis Montastruc, Pierre Petit.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2012 PMID： 22576730 DOI： 10.1007/s00228-012-1299-1

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

× No keyword cloud information.

11 in total

1. Pioglitazone and bladder cancer.

Authors: Dominique Hillaire-Buys; Jean-Luc Faillie; Jean-Louis Montastruc
Journal: Lancet Date: 2011-10-29 Impact factor: 79.321

2. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.

Authors: S Kasichayanula; X Liu; W C Shyu; W Zhang; M Pfister; S C Griffen; T Li; F P LaCreta; D W Boulton
Journal: Diabetes Obes Metab Date: 2011-01 Impact factor: 6.577

3. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats.

Authors: Keiichiro Sato; Yasuyuki Awasaki; Hitoshi Kandori; Zen-Yo Tanakamaru; Hirofumi Nagai; David Baron; Masaki Yamamoto
Journal: Toxicol Appl Pharmacol Date: 2011-01-19 Impact factor: 4.219

Review 4. [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].

Authors: Daniel Duran-Sandoval; Anne-Claire Thomas; Bernard Bailleul; Jean-Charles Fruchart; Bart Staels
Journal: Med Sci (Paris) Date: 2003 Aug-Sep Impact factor: 0.818

5. Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.

Authors: Gerald G Long; Vincent L Reynolds; L Wayne Dochterman; Thomas E Ryan
Journal: Toxicol Pathol Date: 2009-08-21 Impact factor: 1.902

6. PPARalpha and PPARgamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium.

Authors: Frederikke Lihme Egerod; Nils Brünner; Jette E Svendsen; Martin B Oleksiewicz
Journal: J Appl Toxicol Date: 2010-03 Impact factor: 3.446

7. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.

Authors: Ronald A Lubet; Susan M Fischer; Vernon E Steele; M Margaret Juliana; Renee' Desmond; Clinton J Grubbs
Journal: Int J Cancer Date: 2008-11-15 Impact factor: 7.396

Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!

1. Pioglitazone and bladder cancer.

2. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.

3. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats.

Review 4. [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].

5. Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.

6. PPARalpha and PPARgamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium.

7. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.

Review 8. Safety issues and prospects for future generations of PPAR modulators.

9. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.

10. Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.

1. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.

Review 2. Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

3. Pioglitazone use and risk of bladder cancer: population based cohort study.